The national market should receive seven more new Cannabis-based drugs still in 2020. The announcement came from the Brazilian company Onix and the Israeli MGC Pharma, which sealed a partnership this last Tuesday (3).
"Five of the drugs already meet all the requirements of Anvisa (Health Surveillance Agency)", says Marcelo Galvão, founder of Onix, who expects a quick registration process. The expectation is that they start arriving at the pharmacy at the beginning of the second semester.
The other two are in phase 2-B of clinical testing. Therefore, they still have a path until they are forwarded to Anvisa. "I believe they will hit the market only next year," says Galvão.
“All products already have a dossier for registration and stability testing”, says Marcelo Galvão, founder of Onix. The average suggested price will be between $ 150 and $ 250 for the 30 ml bottle. "Depending on the disease, a patient consumes 1 bottle every 15 days or every 45 days."
Unlike conventional medicines, they will reach the market without a fancy name. They are identified as Cannabidiol oil and have different concentrations of CBD and THC molecules. Parkinson's, cancer, epilepsy and Chron's syndrome are some diseases for which they are indicated. Expected revenue is $ 18 million a year, based on an audience of 8,000 patients per month. Below, the table of products.
MXC Price at posting:
2.5¢ Sentiment: Hold Disclosure: Held
